LATEST
Foreign secy Misri meets US lawmakers; Russia sanctions bill and India-US ties in focus✦Managing US, China In An Rising Bi-multipolar World✦Dorothy LGBTQ Climax: Karthik Subbaraj’s Bold Defense?✦Saudi counterterrorism coalition joins Madinah conference✦IPO rush: Trans ACNR Solutions among 9 companies to file preliminary papers with SEBI | Check list✦
Sun, Sep 27, 2026
Loading weather...
Markets

Mirum : FDA Approves Atebrioz For Rare Bone Disorder FOP In Patients Aged 12 And Older

(RTTNews) - Mirum Pharmaceuticals Inc. (MIRM) and Incyte (INCY) announced that the U.S. Food and Drug Administration app...

By Dhallo News · September 27, 2026 at 7:29 PM IST

(RTTNews) - Mirum Pharmaceuticals Inc. (MIRM) and Incyte (INCY) announced that the U.S. Food and Drug Administration approved Atebrioz (zilurgisertib) tablets for reducing the volume of new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older wit

SOURCE: Nasdaq
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion

Read More from Markets

IPO rush: Trans ACNR Solutions among 9 companies to file preliminary papers with SEBI | Check list

Nine companies, including Trans ACNR Solutions and Maharashtra Oil Extractions, ...

Read Article »

Paramount Warner Deal Tests Hollywood’s Future

Bloomberg entertainment reporter Lucas Shaw is on Bloomberg This Weekend examini...

Read Article »

FDA Maintains U.S. Enrollment Hold On Newron's Phase 3 ENIGMA-TRS 2 Schizophrenia Study

(RTTNews) - Newron Pharmaceuticals (NP5.DE, NWRN.SW) said the U.S. Food and Drug...

Read Article »
Return to Front Page

5 minutes. The news that matters.

Get the most important stories of the day, without having to browse hundreds of articles.